Your search history is turned on.
Date: April 10, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
Produced by RDG Portal Proof Builder UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 __________________ FORM8-K CURRENTREPORT PursuanttoSection13OR15(d)ofTheSecuritiesExchangeActof1934 __________________ DateofReport(Dateofearliesteventreported):April5,2024 ___________________ DIAMEDICATHERAPEUTICSINC. (Exactnameofregi...
Date: April 4, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
Dear Shareholders, As we reflect on DiaMedica's journey throughout 2023, we believe we are now strategically positioned to execute on our commitment to advancing the treatment of acute ischemic stroke (AIS) with our therapeutic candidate, DM199 (Rinvecalinase Alfa), the first pharmaceutically active recombinant form of the human tissue kallikrein-1 (rKLK1) protein to be...
dmtp20240329_def14a.htm ...
dmtp20240329_def14a.htm UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 SCHEDULE14A PROXYSTATEMENTPURSUANTTOSECTION14(a)OFTHE SECURITIESEXCHANGEACTOF1934 FiledbytheRegistrant FiledbyaPartyotherthantheRegistrant Checktheappropriatebox: PreliminaryProxyStatement Confidential,forUseoftheCommissio...
dmtp20240329_def14a.htm NOTICEOFANNUALGENERALMEETINGOFSHAREHOLDERS May22,2024 TheAnnualGeneralMeetingofShareholdersofDiaMedicaTherapeuticsInc.,acorporationexistingunderthelawsofBritishColumbia,willbeheldatourcorporate officeslocatedat301CarlsonParkway,Suite210,Minneapolis,Minnesota55305,USA,beginningat9:00a.m.,CDT,on...
Date: March 19, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
dmtp20231231_10k.htm UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2023 or TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperi...
dmtp20231231_10k.htm Exhibit31.2 CERTIFICATIONPURSUANTTOSECTION302(A)OFTHE SARBANES-OXLEYACTOF2002 I,ScottKellen,certifythat: 1.IhavereviewedthisannualreportonForm10-KofDiaMedicaTherapeuticsInc. 2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterialfactneces...
dmtp20231231_10k.htm Exhibit31.1 CERTIFICATIONPURSUANTTOSECTION302(A)OFTHE SARBANES-OXLEYACTOF2002 I,RickPauls,certifythat: 1.IhavereviewedthisannualreportonForm10-KofDiaMedicaTherapeuticsInc. 2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterialfactne...
Date: March 19, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, KELLEN, Scott, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable...